Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021
Introduction and Objectives: Treatment of chronic hepatitis B (CHB) with nucelos(t)ide analogues (NA) can improve outcomes, but NA treatment is expensive for insurance plans. Materials and Methods: The Centers for Medicare & Medicaid Services database was assessed from 2012 to 2021 to assess...
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
Elsevier
2024-07-01
|
| Serie: | Annals of Hepatology |
| Ämnen: | |
| Länkar: | http://www.sciencedirect.com/science/article/pii/S166526812400303X |